



To whom it may concern

October 13, 2009

NanoCarrier Co., Ltd.

Ichiro Nakatomi, Ph.D., President & CEO

(Code No.; 4571 Tokyo Stock Exchange Mothers)

Toshiki Kaura, Head of President's Office

TEL. +81-3-3548-0217

### **Comprehensive Joint Research Agreement with MEDINET for New Cancer Therapies**

We are pleased to announce that NanoCarrier concluded the comprehensive joint research agreement with MEDINET. This is aiming at developing new drugs or technologies in oncology area, integrating technologies, intellectual properties, know-how and research networks of both companies.

NanoCarrier will focus on innovative researches with MEDINET for difficult-to-treat cancers, integrating,

- NanoCarrier's technology of micellar nanoparticles for medical use particularly protein containing micelles.
- MEDINET's technologies and know-how of "Immuno-Cell Therapy" and cell engineering for cancer.
- Research networks of both companies.

We primarily focus on the development of innovative cancer treatments with new concepts, such as,

- New combination treatments with cytokine<sup>1)</sup> containing micelles and immune-cell therapies using effector cells and antigen presenting cells.
- New technologies or medicines targeting on stem cells resistant to anti-cancer drugs.

NanoCarrier is a biotech company, working for R&D of nano-micellar medicines and gene therapies as a pioneer of nano-micellar technology. Nano-micellar medicines based on Japan originated nano-technology are characterized as

- Less toxicity by controlled release of drugs from micellar nano-particles<sup>2)</sup>.
- Better efficacy by high drug accumulation in tumors.

Thus the technology is expected to create high value-added anticancer drugs.

MEDINET provides medical institutions "Immuno-Cell Therapy Total Support Service"<sup>3)</sup>, including technologies, know-how and resources for "Immuno-Cell Therapy". "Immuno-Cell Therapy" is a new innovative technology applied to clinical use, which can maintain good QoL (Quality of Life) of cancer patients and attach cancer cells at molecular level. MEDINET is working aggressively on the research and technology development to improve the efficacy and safety of "Immuno-Cell Therapy".

1) Cytokine

A category of proteins, produced by some cells, control body functions which are immune system, anti-tumor activity, hematopoiesis and etc.

2) Micellar nano-particle

Micelle is an aggregate of substances forming a ball-like structure with hydrophobic tails hiding inside. It is called "Micellar nano-particle" when its size is an order of nano meter (1/billion meter). Nano-micellar technology is an integrated technology of high-molecular chemistry and nano technology.

3) Immuno-Cell Therapy Total Support Service

Comprehensive solution for medical institutions to conduct "Immuno-Cell Therapy", including technical know-how, facilities, systems, materials, cell engineers, information and other resources.